<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05066412</url>
  </required_header>
  <id_info>
    <org_study_id>Cd45RA depleted DLI</org_study_id>
    <nct_id>NCT05066412</nct_id>
  </id_info>
  <brief_title>Prophylactic CD45RA-depleted DLI After Haploidentical Transplantation/RIC</brief_title>
  <official_title>A Phase I Clinical Trial Assessing Prophylactic Donor CD45RA-depleted Lymphocyte Infusions Into Patients Transplanted With Stem Cell Grafts From Haploidentical Donors After Reduced Intensity Conditioning</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess safety of prophylactic escaladed dose of T naïve depleted (CD45RA depleted donor&#xD;
      lymphocyte infusion, in patients with malignant hemopathie who received an allogeneic stem&#xD;
      cell transplant from an haplo-identical donor, after a reduced intensity conditionning&#xD;
      regiment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective is to determine whether the administration of prophylactic CD45RAneg&#xD;
      (CD45RAneg) memory/effector T lymphocytes is feasible and safe in the early post-transplant&#xD;
      period for patients with haploidentical transplant and RIC conditioning.&#xD;
&#xD;
      Donor lymphocytes are isolated from the original donor by non-mobilized mononuclear cell&#xD;
      leukapheresis. Repetitive intravenous infusions (up to 3) of escalating doses of CD45RAneg&#xD;
      cells, prepared from the leukapheresis by CliniMACS® technology (CD45RA-depletion), storage&#xD;
      in vapor nitrogen.&#xD;
&#xD;
      Escalating doses of CD45RAneg cells, for patients with haploidentical graft, intervals of 6-8&#xD;
      weeks, if GvHD is absent starting ≥ 4 weeks from the day of transplantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2021</start_date>
  <completion_date type="Anticipated">December 2, 2026</completion_date>
  <primary_completion_date type="Anticipated">June 2, 2026</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>acute transfusion reaction (CTCAE ≥ 2)</measure>
    <time_frame>24 hours after each CD45RA neg DLI infusion</time_frame>
    <description>acute transfusion reaction after each DLI infusion (CTCAE ≥ 2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>acute GvHD grade II-IV</measure>
    <time_frame>within 8 weeks after each CD45RAneg DLI infusion</time_frame>
    <description>acute GvHD grade II-IV measured with MAGIC score</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Hematologic Malignancy</condition>
  <condition>Haplo-identical Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prophylactic CD45RA-depleted DLI</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CD45RAneg cells, prepared from mononuclear cell leukapheresis by CliniMACS® technology</intervention_name>
    <description>CD45RAneg cells, prepared from mononuclear cell leukapheresis by CliniMACS® technology</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who received a stem cell graft from a haploidentical donor after RIC for&#xD;
             hematologic malignancies&#xD;
&#xD;
          -  Written informed consent of patient and donor obtained&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant taking Prednisone (or equivalent steroid)&#xD;
&#xD;
          -  Participant taking Prednisone (or equivalent steroid)&#xD;
&#xD;
          -  Participant taking Mycophenolate Mofetil&#xD;
&#xD;
          -  Participant taking Cyclosporine/tacrolimus at therapeutic blood levels&#xD;
&#xD;
          -  Progressive hematologic malignancy before transplant&#xD;
&#xD;
          -  Second allogeneic transplant&#xD;
&#xD;
          -  Acute GvHD ≥ grade 2&#xD;
&#xD;
          -  Chronic moderate or severe GvHD (NIH consensus criteria)&#xD;
&#xD;
          -  Hematologic or molecular relapse of the primary malignancy requiring chemotherapy or&#xD;
             unmanipulated DLI (receiving prophylactic antileukemic agent, eg TKI, is not an&#xD;
             exclusion criteria)&#xD;
&#xD;
          -  Donor aberrant CD45RA expression due to a polymorphism in CD45 gene&#xD;
&#xD;
          -  Participation in another interventional clinical trial within 30 days prior to&#xD;
             inclusion&#xD;
&#xD;
          -  Pregnant or nursing women. Sexually active women with childbearing potential as well&#xD;
             as sexually active male patients who are unwilling to use an effective method of&#xD;
             contraception during participation in the study from time of inclusion until 2 months&#xD;
             after last dose of CD45RAneg DLI infusion&#xD;
&#xD;
          -  Inability to follow the procedures of the study, including, but not limited to,&#xD;
             language problems, psychological disorders, dementia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 9, 2021</study_first_submitted>
  <study_first_submitted_qc>October 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2021</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Anne-Claire Mamez</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

